Article
Efficacy of BRAF-Inhibitor Therapy in BRAFV600E -Mutated Adult Langerhans Cell Histiocytosis.
The oncologist - 1 Dec 2020
Hazim Antonious Z, Ruan Gordon J, Ravindran Aishwarya, Abeykoon Jithma P, Scheckel Caleb, Vassallo Robert, Ryu Jay H, Tobin W Oliver, Koster Matthew J, Bennani N Nora, Rech Karen L, Young Jason R, Shah Mithun V, Goyal Gaurav, Go Ronald S
Abstract excerpt
Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration-approved treatments in adult LCH to establish optimal first-line therapy. We conducted a retrospective, single-center case series evaluating the use of BRAF inhibitors in adult patients with BRAFV600E - LCH proven by biopsy. Our case series is the first to report the use of BRAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.